Bicalutamide
Overview
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Plasma protien binding is 96%. Renal Excretion accounts for 1.4-2% and plasma half life is 7-10 days.
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Bicalutamide's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 50 mg | 50 (50) | As recommended. | PO | Daily with orchidectomy or gonadorelin therapy. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Bicalutamide is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Bicalutamide is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Bicalutamide
Back to top
Previous Drug Generic - Next Drug Generic